The DOI matches its Crossref record; 198 of the 198 references it cites were found in a registry or an index.
RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions
Open accessAbstract
RGD peptide can be found in cell adhesion and signaling proteins, such as fibronectin, vitronectin, and fibrinogen. RGD peptides' principal function is to facilitate cell adhesion by interacting with integrin receptors on the cell surface. They have been intensively researched for use in biotechnology and medicine, including incorporation into biomaterials, conjugation to medicinal molecules or nanoparticles, and labeling with imaging agents. RGD peptides can be utilized to specifically target cancer cells and the tumor vasculature by engaging with these integrins, improving drug delivery efficiency and minimizing adverse effects on healthy tissues. RGD‐functionalized drug carriers are a viable option for cancer therapy as this focused approach has demonstrated promise in the future. Writing a review on the RGD peptide can significantly influence how drugs are developed in the future by improving our understanding of the peptide, finding knowledge gaps, fostering innovation, and making drug design easier.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Yan, C., Yang, Q., & Gong, Z. (2018) · Neoplasia · doi:10.1016/j.neo.2018.02.002 · Cited by 21
RetractedSudha, T., Godugu, K., Glinsky, G. V., & Mousa, S. A. (2022) · Biomedicines · doi:10.3390/biomedicines10040795 · Cited by 7
RetractedNew Perspectives in Cell Adhesion: RGD and Integrins
Ruoslahti, E., & Pierschbacher, M. D. (1987) · Science · doi:10.1126/science.2821619 · Cited by 4,865
Targeting integrin pathways: mechanisms and advances in therapy
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01259-6 · Cited by 1,275
Biopharmaceutical benchmarks 2014
Walsh, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3040 · Cited by 1,008
RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis
Danhier, F., Le Breton, A., & Préat, V. (2012) · Molecular Pharmaceutics · doi:10.1021/mp3002733 · Cited by 955
Molecular subtypes of pancreatic cancer
Collisson, E. A., Bailey, P., Chang, D. K., & Biankin, A. V. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0109-y · Cited by 892
Advantages of RGD peptides for directing cell association with biomaterials
Bellis, S. L. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.02.029 · Cited by 745
Mas-Moruno, C., Rechenmacher, F., & Kessler, H. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010794728639 · Cited by 647
Cheresh, D. A., & Spiro, R. C. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45436-1 · Cited by 565
Exploring the Role of RGD-Recognizing Integrins in Cancer
Nieberler, M., Reuning, U., Reichart, F., Notni, J., Wester, H.-J., Schwaiger, M., Weinmüller, M., Räder, A., Steiger, K., & Kessler, H. (2017) · Cancers · doi:10.3390/cancers9090116 · Cited by 429
Meyer, A., Auernheimer, J., Modlinger, A., & Kessler, H. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206777947740 · Cited by 291
Integrin α5β1 facilitates cancer cell invasion through enhanced contractile forces
Mierke, C. T., Frey, B., Fellner, M., Herrmann, M., & Fabry, B. (2011) · Journal of Cell Science · doi:10.1242/jcs.071985 · Cited by 270
Zitzmann, S., Ehemann, V., & Schwab, M. (2002) · PubMed · Cited by 265
Ludwig, B. S., Kessler, H., Kossatz, S., & Reuning, U. (2021) · Cancers · doi:10.3390/cancers13071711 · Cited by 238
Koivisto, L., Heino, J., Häkkinen, L., & Larjava, H. (2014) · Advances in Wound Care · doi:10.1089/wound.2013.0436 · Cited by 234
Liu, M., Li, C., Pazgier, M., Li, C., Mao, Y., Lv, Y., Gu, B., Wei, G., Yuan, W., Zhan, C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008930107 · Cited by 228
Radiolabelled RGD peptides for imaging and therapy
Gaertner, F. C., Kessler, H., Wester, H.-J., Schwaiger, M., & Beer, A. J. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2028-1 · Cited by 227
Teesalu, T., Sugahara, K. N., & Ruoslahti, E. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00216 · Cited by 207
Integrin signalling and function in immune cells
Zhang, Y., & Wang, H. (2012) · Immunology · doi:10.1111/j.1365-2567.2011.03549.x · Cited by 206
Solution stability of linear vs. cyclic RGD peptides
Bogdanowich‐Knipp, S. J., Chakrabarti, S., Siahaan, T. J., Williams, T. D., & Dillman, R. K. (1999) · The Journal of Peptide Research · doi:10.1034/j.1399-3011.1999.00052.x · Cited by 206
Kibria, G., Hatakeyama, H., Ohga, N., Hida, K., & Harashima, H. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.03.012 · Cited by 200
Oba, M., Fukushima, S., Kanayama, N., Aoyagi, K., Nishiyama, N., Koyama, H., & Kataoka, K. (2007) · Bioconjugate Chemistry · doi:10.1021/bc0700133 · Cited by 197
Schnittert, J., Bansal, R., Storm, G., & Prakash, J. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.020 · Cited by 188
Beer, A. J., Niemeyer, M., Carlsen, J., Sarbia, M., Nährig, J., Watzlowik, P., Wester, H.-J., Harbeck, N., & Schwaiger, M. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045526 · Cited by 174
Vaidya, A. M., Sun, Z., Ayat, N., Schilb, A., Liu, X., Jiang, H., Sun, D., Scheidt, J., Qian, V., He, S., et al. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00028 · Cited by 169
Kumar, A., Huo, S., Zhang, X., Liu, J., Tan, A., Li, S., Jin, S., Xue, X., Zhao, Y., Ji, T., et al. (2014) · ACS Nano · doi:10.1021/nn500152u · Cited by 162
Targeting Integrins for Cancer Therapy - Disappointments and Opportunities
Bergonzini, C., Kroese, K., Zweemer, A. J. M., & Danen, E. H. J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.863850 · Cited by 156
Jung, J. P., Jones, J. L., Cronier, S. A., & Collier, J. H. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.01.008 · Cited by 151
Alipour, M., Baneshi, M., Hosseinkhani, S., Mahmoudi, R., Arabzadeh, A. J., Akrami, M., Mehrzad, J., & Bardania, H. (2019) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36862 · Cited by 145
RGD peptide-based non-viral gene delivery vectors targeting integrin α v β 3 for cancer therapy
Fu, S., Xu, X., Ma, Y., Zhang, S., & Zhang, S. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2018.1455841 · Cited by 139
Buerkle, M. A., Pahernik, S. A., Sutter, A., Jonczyk, A., Messmer, K., & Dellian, M. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600141 · Cited by 130
RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy
Sheikh, A., Md, S., & Kesharwani, P. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.028 · Cited by 119
Function and Mechanism of RGD in Bone and Cartilage Tissue Engineering
Yang, M., Zhang, Z., Liu, Y., Chen, Y., Deng, R., Zhang, Z., Yu, J., & Yuan, F. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.773636 · Cited by 117
Design of Functional RGD Peptide-Based Biomaterials for Tissue Engineering
Kumar, V. B., Tiwari, O. S., Finkelstein‐Zuta, G., Rencus‐Lazar, S., & Gazit, E. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020345 · Cited by 115
The development of site-specific drug delivery nanocarriers based on receptor mediation
Wang, X., Li, S., Shi, Y., Chuan, X., Li, J., Zhong, T., Zhang, H., Dai, W., He, B., & Zhang, Q. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.028 · Cited by 114
RGD Peptide‐Based Target Drug Delivery of Doxorubicin Nanomedicine
Sun, Y., Chen, K., Liu, F., Zhou, Y., Luo, L., & Qiao, H. (2017) · Drug Development Research · doi:10.1002/ddr.21399 · Cited by 113
Delbaldo, C., Raymond, É., Vera, K., Hammershaimb, L., Kaucic, K., Lozahic, S., Marty, M. E., & Faivre, S. J. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9077-0 · Cited by 101
Structural and mechanical functions of integrins
Anderson, L. R., Owens, T. W., & Naylor, M. J. (2013) · Biophysical Reviews · doi:10.1007/s12551-013-0124-0 · Cited by 100
iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers
Zuo, H.-D. (2019) · Journal of Oncology · doi:10.1155/2019/9367845 · Cited by 100
RGD-QD-MoS 2 nanosheets for targeted fluorescent imaging and photothermal therapy of cancer
Zhang, Y., Xiu, W., Sun, Y., Zhu, D., Zhang, Q., Yuwen, L., Weng, L., Teng, Z., & Wang, L. (2017) · Nanoscale · doi:10.1039/c7nr05278b · Cited by 99
Hamilton, A. M., Aidoudi-Ahmed, S., Sharma, S., Kotamraju, V. R., Foster, P. J., Sugahara, K. N., Ruoslahti, E. I., & Rutt, B. K. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1279-x · Cited by 98
Lahlou, H., & Muller, W. J. (2011) · Breast Cancer Research · doi:10.1186/bcr2905 · Cited by 97
Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin™
Mulgrew, K. A., Kinneer, K., Yao, X.-T., Ward, B. K., Damschroder, M. M., Walsh, B., Mao, S.-Y., Gao, C., Kiener, P. A., Coats, S., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0356 · Cited by 96
68Ga-BBN-RGD PET/CT for GRPR and Integrin αvβ3 Imaging in Patients with Breast Cancer
Zhang, J., Mao, F., Niu, G., Peng, L., Lang, L., Li, F., Ying, H., Wu, H., Pan, B., Zhu, Z., et al. (2018) · Theranostics · doi:10.7150/thno.22601 · Cited by 95
The effect of conformation on the solution stability of linear vs. cyclic RGD peptides
Bogdanowich-Knipp, S. J., JOIS, D. S. S., & Siahaan, T. J. (1999) · Journal of Peptide Research · doi:10.1034/j.1399-3011.1999.00055.x · Cited by 94
Integrin-Targeting Peptides for the Design of Functional Cell-Responsive Biomaterials
Zhao, J., Santino, F., Giacomini, D., & Gentilucci, L. (2020) · Biomedicines · doi:10.3390/biomedicines8090307 · Cited by 94
Zang, J., Wen, X., Lin, R., Zeng, X., Wang, C., Shi, M., Zeng, X., Zhang, J., Wu, X., Zhang, X., et al. (2022) · Theranostics · doi:10.7150/thno.79144 · Cited by 94
Integrins regulate stemness in solid tumor: an emerging therapeutic target
Xiong, J., Yan, L., Zou, C., Wang, K., Chen, M., Xu, B., Zhou, Z., & Zhang, D. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01192-1 · Cited by 92
Akashi, Y., Oda, T., Ohara, Y., Miyamoto, R., Kurokawa, T., Hashimoto, S., Enomoto, T., Yamada, K., Satake, M., & Ohkohchi, N. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.49 · Cited by 90
RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy
Ji, S., Xu, J., Zhang, B., Yao, W., Xu, W., Wu, W., Xu, Y., Wang, H., Ni, Q., Hou, H., et al. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.13.4.18692 · Cited by 89
Cao, J., Li, J., Sun, L., Qin, T., Xiao, Y., Chen, K., Qian, W., Duan, W., Lei, J., Ma, J., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12399 · Cited by 89
Research advances on structure and biological functions of integrins
Pan, L., Zhao, Y., Yuan, Z., & Qin, G. (2016) · SpringerPlus · doi:10.1186/s40064-016-2502-0 · Cited by 88
Liu, H., Shi, X., Wu, D., Khshen, F. K., Deng, L., Dong, A., Wang, W., & Zhang, J. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b01987 · Cited by 86
Enhanced effect of autologous EVs delivering paclitaxel in pancreatic cancer
Faruque, H. A., Choi, E., Kim, J., & Kim, E. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.012 · Cited by 86
Fan, J., Liu, B., Long, Y., Wang, Z., Tong, C., Wang, W., You, P., & Liu, X. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.06.025 · Cited by 85
Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates
Worm, D. J., Els‐Heindl, S., & Beck‐Sickinger, A. G. (2020) · Peptide Science · doi:10.1002/pep2.24171 · Cited by 83
Jiang, Q., Pan, Y., Cheng, Y., Li, H., Liu, D., & Li, H. (2016) · Oncology Reports · doi:10.3892/or.2016.4798 · Cited by 82
Rgd-Mediated Delivery of Small-Molecule Drugs
Katsamakas, S., Chatzisideri, T., Thysiadis, S., & Sarli, V. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0008 · Cited by 82
Self-delivery of a peptide-based prodrug for tumor-targeting therapy
Peng, M., Qin, S., Jia, H., Zheng, D., Rong, L., & Zhang, X. (2015) · Nano Research · doi:10.1007/s12274-015-0945-1 · Cited by 81
New opportunities for RGD-engineered metal nanoparticles in cancer
Qin, W., Chandra, J., Abourehab, M. A. S., Gupta, N., Chen, Z., Kesharwani, P., & Cao, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01784-0 · Cited by 81
Integrin Structure and Function
Srichai, M. B., & Zent, R. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0814-8_2 · Cited by 80
Bock, N., Forouz, F., Hipwood, L., Clegg, J., Jeffery, P. L., Gough, M., van Wyngaard, T., Pyke, C., Adams, M. N., Bray, L. J., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010261 · Cited by 80
Modulating angiogenesis with integrin-targeted nanomedicines
Duro‐Castaño, A., Gallon, E., Decker, C. G., & Vicent, M. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.008 · Cited by 79
Zheng, Y., Ji, S., Czerwiński, A. A., Valenzuela, F., Pennington, M. W., & Liu, S. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500452y · Cited by 76
Lin, W., Ma, G., Yuan, Z., Qian, H., Xu, L., Sidransky, E., & Chen, S. (2018) · Langmuir · doi:10.1021/acs.langmuir.8b00851 · Cited by 74
Lin, Y., Zhong, Y., Chen, Y., Li, L., Chen, G., Zhang, J., Li, P., Zhou, C., Sun, Y., Ma, Y., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00421 · Cited by 74
Recent Progress of RGD Modified Liposomes as Multistage Rocket Against Cancer
Sheikh, A., Alhakamy, N. A., Md, S., & Kesharwani, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.803304 · Cited by 71
Nanoparticles-mediated CRISPR/Cas9 delivery: Recent advances in cancer treatment
Aghamiri, S., Talaei, S., Ghavidel, A. A., Zandsalimi, F., Masoumi, S., Hafshejani, N. H., & Jajarmi, V. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101533 · Cited by 70
RGD Peptide‐Drug Conjugates as Effective Dual Targeting Platforms: Recent Advances
Battistini, L., Bugatti, K., Sartori, A. M., Curti, C., & Zanardi, F. (2021) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202100240 · Cited by 70
Serie, D., Joseph, R. W., Cheville, J. C., Ho, T. H., Parasramka, M. A., Hilton, T. W., Thompson, R. H., Leibovich, B. C., Parker, A. S., & Eckel‐Passow, J. E. (2016) · European Urology · doi:10.1016/j.eururo.2016.11.018 · Cited by 69
Monti, M., Rosa, V. D., Iommelli, F., Carriero, M. V., Terlizzi, C., Camerlingo, R., Belli, S., Fonti, R., Minno, G. D., & Vecchio, S. D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082350 · Cited by 69
Palanikumar, L., Kim, H. Y., Oh, J. Y., Thomas, A. P., Choi, E. S., Jeena, M. T., Joo, S. H., & Ryu, J. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b00589 · Cited by 66
Tselepis, V. H., Green, L. J., & Humphries, M. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21341 · Cited by 63
Gong, Z., Liu, X., Zhou, B., Wang, G., Guan, X., Xu, Y., Zhang, J., Hong, Z., Cao, J., Sun, X., et al. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111673 · Cited by 62
Garg, A., & Kokkoli, E. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111796117328 · Cited by 60
Genome analyses identify the genetic modification of lung cancer subtypes
Zhang, Y., Wang, D. C., Shi, L., Zhu, B., Min, Z., & Jin, J. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.11.005 · Cited by 58
Liposomes with cyclic RGD peptide motif triggers acute immune response in mice
Wang, X., Wang, H., Jiang, K., Zhang, Y., Zhan, C., Ying, M., Zhang, M., Lu, L., Wang, R., Wang, S., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.003 · Cited by 56
Knetsch, P. A., Zhai, C., Rangger, C. A., Blatzer, M., Haas, H., Kaeopookum, P., Haubner, R., & Decristoforo, C. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.10.001 · Cited by 56
He, T., He, J., Younis, M. R., Blum, N. T., Lei, S., Zhang, Y., Huang, P., & Lin, J. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c03211 · Cited by 56
Greenspoon, N., Hershkoviz, R., Alon, R., Varon, D., Shenkman, B. S., Marx, G. S., Federman, S., Kapustina, G., & Lider, O. (1993) · Biochemistry · doi:10.1021/bi00055a002 · Cited by 55
Gai, Y., Jiang, Y., Yu, L., Sun, L., Liu, Q., Qin, C., Zhang, Y., Zeng, D., & Lan, X. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01134 · Cited by 55
RGD peptide-based lipids for targeted mRNA delivery and gene editing applications
Qin, J., Xue, L., Gong, N., Zhang, H., Shepherd, S. J., Haley, R. M., Swingle, K. L., & Mitchell, M. J. (2022) · RSC Advances · doi:10.1039/d2ra02771b · Cited by 54
Yang, X., Wang, L., Li, L., Han, M., Tang, S., Wang, T., Han, J., He, X., He, X., Wang, A., et al. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1667455 · Cited by 52
Recent Research Progress of RGD Peptide–Modified Nanodrug Delivery Systems in Tumor Therapy
Yin, L., Li, X., Wang, R., Zeng, Y., Zeng, Z., & Xie, T. (2023) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-023-10523-4 · Cited by 52
An RGD Motif Present in Cadherin 17 Induces Integrin Activation and Tumor Growth
Bartolomé, R. A., Peláez‐García, A., Gomez, I., Torres, S., Fernández‐Aceñero, M. J., Escudero-Paniagua, B., Imbaud, J. I., & Casal, J. I. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.600502 · Cited by 51
Sorolla, A., Wang, E., Clemons, T. D., Evans, C. W., Plani-Lam, J. H. C., Golden, E., Dessauvagie, B., Redfern, A. D., Swaminathan-Iyer, K., & Blancafort, P. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.04.006 · Cited by 51
Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors
Li, L., Chen, X. S., Yu, J., & Yuan, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837952 · Cited by 50
Structure–Activity Relationships of RGD-Containing Peptides in Integrin αvβ5-Mediated Cell Adhesion
Yamada, Y., Onda, T., Wada, Y., Hamada, K., Kikkawa, Y., & Nomizu, M. (2023) · ACS Omega · doi:10.1021/acsomega.2c06540 · Cited by 50
Mansur, A. A. P., Rodrigues, M. A., Capanema, N. S. V., Carvalho, S. M., Gomes, D. A., & Mansur, H. S. (2023) · RSC Advances · doi:10.1039/d3ra01519j · Cited by 50
Heterogeneity of lipidomic profiles among lung cancer subtypes of patients
Lv, J., Gao, D., Zhang, Y., Wu, D., Shen, L., & Wang, X. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13782 · Cited by 48
Campbell, P. S., Mavingire, N., Khan, S., Rowland, L. K., Wooten, J. V., Opoku‐Agyeman, A., Guevara, A., Soto, U., Cavalli, F., Loaiza‐Perez, A., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27013 · Cited by 48
Chakravarty, R., Chakraborty, S., Guleria, A., Kumar, C., Kunwar, A., Nair, K. V. V., Sarma, H. D., & Dash, A. K. (2019) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2019.05.005 · Cited by 48
Steiger, K., Quigley, N. G., Groll, T., Richter, F., Zierke, M. A., Beer, A. J., Weichert, W., Schwaiger, M., Kossatz, S., & Notni, J. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00842-2 · Cited by 48
Peptide‐based hydrogels as delivery systems for doxorubicin
Diaferia, C., Rosa, E., Accardo, A., & Morelli, G. (2021) · Journal of Peptide Science · doi:10.1002/psc.3301 · Cited by 47
Cho, H.-J., Lee, S.-J., Park, S. J., Paik, C. H., Lee, S.-M., Kim, S., & Lee, Y.-S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.032 · Cited by 45
Geometry encoded functional programming of tumor homing peptides for targeted drug delivery
Goyal, R., Jerath, G., Akhil, R., Chandrasekharan, A., Puppala, E. R., Ponneganti, S., Sarma, A., Naidu, V. G. M., Santhoshkumar, T. R., & Ramakrishnan, V. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.010 · Cited by 45
Molecular Modeling Insights into the Structure and Behavior of Integrins: A Review
Tvaroška, I., Kozmon, S., & Kóňa, J. (2023) · Cells · doi:10.3390/cells12020324 · Cited by 44
Park, H. J., & Helfman, D. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-56276-3 · Cited by 43
Implantation of hydrogel-liposome nanoplatform inhibits glioblastoma relapse by inducing ferroptosis
Wang, Z., Liu, Z., Wang, S., Bing, X., Ji, X., He, D., Han, M., Wei, Y., Wang, C., Qian, X., et al. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100800 · Cited by 43
Grigoryeva, E. S., Таширева, Л. А., Savelieva, O. E., Zavyalova, M. V., Popova, N. O., Kuznetsov, G. A., Сергеевна, А. Е., & Михайлович, П. В. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032929 · Cited by 42
Xin, L., Yuan, Y., Liu, C., Zhou, L., Liu, L., Zhou, Q., & Li, S.-H. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06262-x · Cited by 41
Design of integrin αvβ3 targeting self-assembled protein nanoparticles with RGD peptide
Lv, X., Zhang, C., Shuaizhen, Q., Yu, R., & Zheng, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110236 · Cited by 41
Enhancing native chemical ligation for challenging chemical protein syntheses
Giesler, R. J., Erickson, P. W., & Kay, M. S. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.04.003 · Cited by 41
RGD-engineered nanoparticles as an innovative drug delivery system in cancer therapy
Sanati, M., Afshari, A. R., Aminyavari, S., Kesharwani, P., Jamialahmadi, T., & Sahebkar, A. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104562 · Cited by 40
Schwab, E. H., Halbig, M., Glenske, K., Wagner, A., Wenisch, S., & Cavalcanti‐Adam, E. A. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.6908 · Cited by 39
Khabazian, E., Vakhshiteh, F., Norouzi, P., Fatahi, Y., Dinarvand, R., & Atyabi, F. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.1973481 · Cited by 39
Mi, X., Du, H., Guo, X., Wu, Y., Shen, L., Luo, Y., Wang, D., Su, Q., Xiang, R., Yue, S., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.01.023 · Cited by 39
Investigating the role of peptides in effective therapies against cancer
Naeimi, R., Bahmani, A., & Afshar, S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02553-7 · Cited by 39
Zhang, Q., Zhang, Y., Li, K., Wang, H., Li, H., & Zheng, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129865 · Cited by 38
Zuo, H. D., Yao, W. W., Chen, T. W., Zhu, J., Zhang, J. J., Pu, Y., Liu, G., & Zhang, X. M. (2014) · BioMed Research International · doi:10.1155/2014/852352 · Cited by 38
Quigley, N. G., Tomassi, S., Leva, F. S. D., Maro, S. D., Richter, F., Steiger, K., Kossatz, S., Marinelli, L., & Notni, J. (2020) · ChemBioChem · doi:10.1002/cbic.202000200 · Cited by 38
Shetake, N. G., Ali, M., Kumar, A., Bellare, J., & Pandey, B. N. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.213147 · Cited by 38
Bioresorbable Polymersomes for Targeted Delivery of Cisplatin
Petersen, M. A., Hillmyer, M. A., & Kokkoli, E. (2013) · Bioconjugate Chemistry · doi:10.1021/bc3003259 · Cited by 37
Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through α5β1 Integrin
Pelillo, C., Bergamo, A., Mollica, H., Bestagno, M., & Sava, G. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25189 · Cited by 37
Improved Anti-Triple Negative Breast Cancer Effects of Docetaxel by RGD-Modified Lipid-Core Micelles
Chen, R., Ni, S., Chen, W., Liu, M., Feng, J., & Hu, K. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s313166 · Cited by 37
Geng, T., Leung, E. Y., Chamley, L. W., & Wu, Z. (2023) · Biomaterials Advances · doi:10.1016/j.bioadv.2023.213388 · Cited by 37
Zhang, X., Du, R., Zhong, T., Zhang, W.-Q., Song, P., Song, W.-D., Zhao, Y., Wang, C., Tang, Y., & Zhang, Q. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s65664 · Cited by 36
Bardania, H., Shojaosadati, S. A., Kobarfard, F., Dorkoosh, F. A., Zadeh, M. E., Naraki, M., & Faizi, M. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1440-6 · Cited by 36
Qian, J., Zhou, S., Lin, P., Lei, J., Zheng, S., Xu, W., Wang, Y., Gao, Z., & Yang, J.-L. (2023) · Drug Development Research · doi:10.1002/ddr.22056 · Cited by 36
Kato, N., Sato, T., Fuchigami, Y., Suga, T., Geng, L., Tsurumaru, M., Hagimori, M., Mukai, H., & Kawakami, S. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106239 · Cited by 35
Marić, I., Yang, L., Li, X., Santiago, G. M., Pappas, C. G., Qiu, X., Dijksman, J. A., Mikhailov, K. I., van Rijn, P., & Otto, S. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202216475 · Cited by 35
Yang, B., Gao, J., Rao, Z.-Y., & Shen, Q. (2013) · Neoplasma · doi:10.4149/neo_2013_034 · Cited by 34
Li, J., Ji, J., Holmes, L. M., Burgin, K. E., Barton, L. B., Yu, X., Wagner, T. E., & Wei, Y. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700707 · Cited by 34
Sarin, V., Gaffin, R. D., Meininger, G. A., & Muthuchamy, M. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2005.083238 · Cited by 33
Zhang, L., Xing, Y., Gao, Q., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.06.103 · Cited by 33
iRGD‐paclitaxel conjugate nanoparticles for targeted paclitaxel delivery
Hu, H., Wang, B., Lai, C., Xu, X., Zhen, Z., Zhou, H., & Xu, D. (2019) · Drug Development Research · doi:10.1002/ddr.21589 · Cited by 33
Zhao, J., Shi, J., Meng, X., Gong, C., Wu, P., Yang, Z., & Dong, H. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.02.030 · Cited by 33
Bessone, M. I. D., Simón‐Gracia, L., Scodeller, P., Ramírez, M. D. L. Á., Huvelle, M. A. L., Soler‐Illia, G. J. A. A., & Simian, M. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0553-4 · Cited by 32
Du, M., Gu, J., Liu, C., Liu, N., Yu, Z., Zhou, C.-P., Wei, H., Cao, Z., Wei, F., Zhu, K., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02344-y · Cited by 32
Cho, R., Sakurai, Y., Jones, H. S., Akita, H., Hisaka, A., & Hatakeyama, H. (2020) · Cancers · doi:10.3390/cancers12123630 · Cited by 31
Specific Targeting of Human Integrin αvβ3 with 111In-Labeled Abegrin™ in Nude Mouse Models
Liu, Z., Jia, B., Zhao, H., Chen, X. S., & Wang, F. (2010) · Molecular Imaging and Biology · doi:10.1007/s11307-010-0302-4 · Cited by 30
Miskin, R. P., Warren, J., Ndoye, A., Wu, L., Lamar, J. M., & DiPersio, C. M. (2021) · Cancers · doi:10.3390/cancers13030480 · Cited by 30
Suga, T., Kato, N., Hagimori, M., Fuchigami, Y., Kuroda, N., Kodama, Y., Sasaki, H., & Kawakami, S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00476 · Cited by 29
Jia, P., Zhao, X., Liu, Y., Liu, M., Zhang, Q., Chen, S., Huang, H., Jia, Y., Chang, Y., Han, Z., et al. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.138004 · Cited by 29
Tannic acid-loaded chitosan-RGD-alginate scaffolds for wound healing and skin regeneration
Mndlovu, H., du Toit, L. C., Kumar, P., & Choonara, Y. E. (2023) · Biomedical Materials · doi:10.1088/1748-605x/acce88 · Cited by 28
Cano‐Cortés, V., Navarro-Marchal, S. A., Ruiz-Blas, M. P., Díaz‐Mochon, J. J., Marchal, J. A., & Sanchez-Martin, R. M. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.102120 · Cited by 27
Interplay Between Genetic and Epigenetic Changes in Breast Cancer Subtypes
Dumitrescu, R. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8751-1_2 · Cited by 26
The role of viruses in cancer development versus cancer therapy: An oncological perspective
Javid, H., Mashhad, A. S., Yazdani, S., Oryani, M. A., Akbari, S., Rezagholinejad, N., Tajaldini, M., & Karimi‐Shahri, M. (2023) · Cancer Medicine · doi:10.1002/cam4.5694 · Cited by 26
Self-citationRole of anb3 Integrin Receptor in the Invasive Potential of Human Cervical Cancer (SiHa) Cells
Chattopadhyay, N., & Chatterjee, A. (2001) · Journal of Environmental Pathology Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.v20.i3.50 · Cited by 25
Chen, J., Cao, F., Cao, Y., Wei, S., Zhu, X., & Xing, W. (2022) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2022.3278 · Cited by 25
Peptide-based delivery vectors with pre-defined geometrical locks
Goyal, R., Jerath, G., Chandrasekharan, A., et al. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00229a · Cited by 24
Repositioning of Anti-Inflammatory Drugs for the Treatment of Cervical Cancer Sub-Types
Kori, M., Arğa, K. Y., Mardinoğlu, A., & Turanlı, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.884548 · Cited by 24
Zhang, Y., Mo, Y., Zhang, Y., Yuan, J., & Zhang, Q. (2023) · Particle and Fibre Toxicology · doi:10.1186/s12989-023-00532-y · Cited by 24
Mihardja, S. S., Gao, D., Sievers, R. E., Fang, Q., Feng, J., Wang, J., VanBrocklin, H. F., Larrick, J. W., Huang, M. T. F., Dae, M. W., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010384 · Cited by 23
Civera, M., Arosio, D., Bonato, F., Manzoni, L., Pignataro, L., Zanella, S., Gennari, C., Piarulli, U., & Belvisi, L. (2017) · Cancers · doi:10.3390/cancers9100128 · Cited by 23
αvβ3 Integrin Antagonists Enhance Chemotherapy Response in an Orthotopic Pancreatic Cancer Model
Coskun, M. D., Sudha, T., Bharali, D. J., Çelikler, S., Davis, P. J., & Mousa, S. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00095 · Cited by 23
Peptides as Diagnostic, Therapeutic, and Theranostic Tools: Progress and Future Challenges
Thakur, R., Suri, C. R., Kaur, I. P., & Rishi, P. (2022) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2022040322 · Cited by 23
Proteomics analysis of a novel compound: Cyclic RGD in breast carcinoma cell line MCF‐7
Juan, H., I-hsiu, W., Huang, T., Li, J.-J., Chen, S., & Huang, H. (2006) · PROTEOMICS · doi:10.1002/pmic.200500435 · Cited by 22
‘Normalizing’ the malignant phenotype of luminal breast cancer cells via alpha(v)beta(3)-integrin
Abu-Tayeh, H., Weidenfeld, K., Zhilin-Roth, A., Schif‐Zuck, S., Thaler, S., Cotarelo, C., Tan, T. Z., Thiery, J. P., Green, J. E., Klorin, G., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.387 · Cited by 22
Novel Integrin αvβ3-Specific Ligand for the Sensitive Diagnosis of Glioblastoma
Zhang, L., Shan, X., Meng, X., Gu, T., Guo, L., An, X., Jiang, Q. Y., Ge, H., & Ning, X. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00602 · Cited by 22
Cheng, Y., Qin, S., Liu, W., Ma, Y., Chen, X., Zhang, A., & Zhang, X. (2020) · Advanced Materials Interfaces · doi:10.1002/admi.202000935 · Cited by 22
Zhang, J., Su, X., Weng, L., Tang, K., Miao, Y., Teng, Z., & Wang, L. (2022) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2022.11.085 · Cited by 22
RGD peptide modified RBC membrane functionalized biomimetic nanoparticles for thrombolytic therapy
Xu, Z., Huang, J., Zhang, T., Xu, W., Liao, X., Wang, Y., & Wang, G. (2023) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-023-06719-1 · Cited by 22
Qiu, M., Wang, X., Sun, H., Zhang, J., Deng, C., & Zhong, Z. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00498 · Cited by 21
D’Onofrio, P. M., Shabanzadeh, A. P., Choi, B., Bähr, M., & Koeberle, P. D. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-25257 · Cited by 21
Liu, B., Zhang, Z., Wang, H., & Yao, S. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115094 · Cited by 21
Multimeric Presentation of RGD Peptidomimetics Enhances Integrin Binding and Tumor Cell Uptake
Pina, A., Kadri, M., Arosio, D., Corso, A. D., Coll, J., Gennari, C., & Boturyn, D. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202001115 · Cited by 21
Lee, E. J., Ahmad, K., Pathak, S., Lee, S., Baig, M. H., Jeong, J., Doh, K., Lee, D.-M., & Choi, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063042 · Cited by 21
Pirooznia, N., Abdi, K., Beiki, D., Emami, F., Arab, S. S., Sabzevari, O., Parizi, Z. P., & Geramifar, P. (2020) · Contrast Media & Molecular Imaging · doi:10.1155/2020/8421657 · Cited by 20
Wang, X., Meng, N., Wang, S., Lu, L., Wang, H., Zhan, C., Burgess, D. J., & Lu, W. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00394 · Cited by 20
Yamaguchi, A., Anami, Y., Ha, S. Y. Y., Roeder, T. J., Xiong, W., Lee, J., Ueno, N. T., Zhang, N., An, Z., & Tsuchikama, K. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116013 · Cited by 20
Bernhagen, D., Laporte, L. D., & Timmerman, P. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b00554 · Cited by 19
Bolzati, C., Salvarese, N., Carpanese, D., Seraglia, R., Meléndez‐Alafort, L., Rosato, A., Capasso, D., Saviano, M., Gatto, A. D., Comegna, D., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01075 · Cited by 19
RGD Forever!—Past, Present, and Future of a 3-Letter-Code in Radiopharmacy and Life Sciences
Notni, J. (2022) · Pharmaceuticals · doi:10.3390/ph16010056 · Cited by 18
Bourn, M. D., Mohajerani, S. Z., Mavria, G., Ingram, N., Coletta, P. L., Evans, S. D., & Peyman, S. A. (2023) · Lab on a Chip · doi:10.1039/d2lc00963c · Cited by 18
isoDGR-Peptides for Integrin Targeting: Is the Time Up for RGD?
Höltke, C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01123 · Cited by 17
Novel cilengitide-based cyclic RGD peptides as αvβ integrin inhibitors
Meena, C. L., Singh, D., Weinmüller, M., Reichart, F., Dangi, A., Marelli, U. K., Stefan Zahler, A., & Sanjayan, G. J. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127039 · Cited by 17
Versatile Red Blood Cells for Triple‐Negative Breast Cancer Treatment via Stepwise Photoactivations
Cheng, Y., Chen, Q., Qian, Z., Shan, T., Bai, L., Jiang, X., Li, C., & Wang, Y. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202201690 · Cited by 17
Three-armed RGD-decorated starPLA-PEG nanoshuttle for docetaxel delivery
Torcasio, S. M., Oliva, R., Montesi, M., Panseri, S., Bassi, G., Mazzaglia, A., Piperno, A., Coulembier, O., & Scala, A. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.213043 · Cited by 15
Liu, X., Wang, F., Liu, L., Li, T., Zhong, X., Lin, H., Zhang, Y., & Xue, W. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114995 · Cited by 15
Lü, Q., Wang, J., Jiang, J., Wang, S., Jia, Q., Wang, Y., Li, W., Zhou, Q., Lv, L., & Li, Q. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165093 · Cited by 14
Wang, F., Huang, Q., Wang, Y., Zhang, W., Lin, R., Yu, Y., Shen, Y., Cui, H., & Guo, S. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.07.025 · Cited by 14
Ge, F., Qiao, R., Song, P., Tao, Y., Zhu, L., Zhang, W., Li, W., & Gui, L. (2021) · Materials Research Express · doi:10.1088/2053-1591/abed89 · Cited by 14
Liao, L., Cen, B., Li, G., Wei, Y., Wang, Z., Huang, W., He, S., Yuan, Y., & Ji, A. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1937381 · Cited by 14
Mesoporous silica gated mixed micelle for the targeted co-delivery of doxorubicin and paclitaxel
Manjusha, V., Reshma, L. R., & Anirudhan, T. S. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.104032 · Cited by 14
Liu, X., Meng, L., Wang, Z., Yu, Z., Zhang, C., Liu, L., Coen, Z., Yang, Z., & Wu, G. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115207 · Cited by 14
Krishnamoorthy, R., Singh, M., Parthiban, A., Edwin Paul, L., Dhanasekaran, S., & Sathiah, T. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106434 · Cited by 14
Integrin αvβ3-dependent thyroid hormone effects on tumour proliferation and vascularisation
Schmohl, K. A., Han, Y., Tutter, M., Schwenk, N., Sarker, R. S. J., Steiger, K., Ziegler, S. I., Bartenstein, P., Nelson, P. J., & Spitzweg, C. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0353 · Cited by 13
Huang, C., Liu, F.-R., Feng, Q., Pan, X.-Y., Song, S., & Yang, J.-L. (2021) · BMC Cancer · doi:10.1186/s12885-021-08056-4 · Cited by 13
Raut, S. Y., Fu, K., Taichun, H., Gahane, A. Y., Chaudhari, D., Kushwah, V., Managuli, R. S., Hegde, A. R., Jain, S., Kalthur, G., et al. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122868 · Cited by 13
Effects of cilengitide in osteoclast maturation and behavior
Chillà, A., Bianconi, D., Geetha, N., Dorda, A., Poettler, M., Unseld, M., Sykoutri, D., Redlich, K., Zielinski, C. C., & Prager, G. W. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.07.018 · Cited by 12
Bodenberger, N. E., Kubiczek, D. H., Paul, P., Preising, N., Weber, L., Bosch, R., Hausmann, R., Gottschalk, K., & Rosenau, F. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7982-x · Cited by 11
Preclinical evaluation of peptide-based radiotracers for integrin αvβ6-positive pancreatic carcinoma
Müller, M., Altmann, A., Sauter, M., Lindner, T., Jäger, D., Rathke, H. G., Herold‐Mende, C. C., Marmé, F., Babich, J. W., Mier, W., et al. (2019) · Nuklearmedizin - NuclearMedicine · doi:10.1055/a-0894-4127 · Cited by 11
Yu, L., Shao, F., Ji, H., Song, X., Lv, X., Xia, X., Liu, Q., Zhang, Y., Zeng, D., Lan, X., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.884554 · Cited by 11
Fu, J., Xie, Y., Fu, T., Qiu, F., Yu, F., Qu, W., Yao, X., Zhang, A., Yang, Z., Shao, G., et al. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00801-x · Cited by 10
CRGDK-Functionalized PAMAM-Based Drug-Delivery System with High Permeability
Liu, D., Wang, C., Yang, J. Y., An, Y., Yang, R., & Teng, G. (2020) · ACS Omega · doi:10.1021/acsomega.0c00202 · Cited by 9
A stapled chromogranin A-derived peptide homes in on tumors that express αvβ6 or αvβ8 integrins
Monieri, M., Rainone, P., Sacchi, A., Gori, A., Gasparri, A. M., Coliva, A., Citro, A., Ferrara, B., Policardi, M., Valtorta, S., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.76148 · Cited by 9
Kim, J.-E., Lee, S., Park, J., Jung, M., An, S.-E., Yang, H. J., & Chung, W. (2023) · Oncology Reports · doi:10.3892/or.2023.8495 · Cited by 8
Huang, C., Liu, F.-R., Feng, Q., Pan, X.-Y., Song, S., & Yang, J.-L. (2021) · BMC Cancer · doi:10.1186/s12885-021-08120-z · Cited by 7
Zhao, H., Gao, H., Luo, C., Yang, G., Zhao, X., Gao, S., Ma, Q., Jia, B., Shi, J., & Wang, F. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00296 · Cited by 7
Abla, A. B., Boeuf, G., Marjou, A. E., Dridi, C., Poirier, F., Changotade, S., Lutomski, D., & Elm’selmi, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147362 · Cited by 7
Mitsuyuki, K., Watabe, T., Naka, S., Liu, Y., Tatsumi, M., Shimosegawa, E., & Kato, H. (2021) · Diagnostics · doi:10.3390/diagnostics11071295 · Cited by 6
Chen, Z., Fu, H., Wu, H., Huang, J., Yao, L., Zhang, X., & Li, Y. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200424101936 · Cited by 5
Qin, J., Liang, Q. D., Wang, G., Hao, L., Liu, X., Wang, X., Hu, Z., Fang, G., Xue, L., Zhao, Y., et al. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02938-0 · Cited by 5
Zhou, Y., Lv, X., Li, S., Bai, B., & Zhan, L. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2503 · Cited by 4
Wei, X., Lv, R., Wang, X., He, J., & He, J. (2022) · International Journal of Morphology · doi:10.4067/s0717-95022022000601587 · Cited by 3
RGD-Peptides and Some Immunological Problems
Siemion, I. Z., Kluczyk, A., & Cebrat, M. (2006) · Elsevier eBooks · doi:10.1016/b978-012369442-3/50085-4 · Cited by 2
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Metadata
- Authors
- Javid, H., Oryani, M. A., Rezagholinejad, N., Esparham, A., Tajaldini, M., & Karimi‐Shahri, M.
- Venue
- Cancer Medicine
- Publisher
- Wiley
- Published
- 2024-01
- Volume
- 13
- Issue
- 2
- Pages
- e6800-e6800
- ISSN
- 2045-7634 (ISSN-L)
- OpenAlex
- W4391436075
- Cited by
- 277
- References
- 198
- FWCI
- 72.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.